Passage BIO, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Passage BIO, Inc. (Nasdaq: PASG) on September 9, 2024. The report discloses the appointment of a new director and associated compensatory arrangements. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to director compensation: non-incentive stock options with a Grant Date fair value of $90,000.
Material Changes
On September 9, 2024, the Board of Directors appointed Thomas Kassberg as a Class I director and a member of the Audit Committee, effective September 10, 2024. Mr. Kassberg brings extensive experience from Ultragenyx Pharmaceutical Inc., where he currently serves as Chief Business Officer and Executive Vice President.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding the Company's business operations or financial future. It details the terms of Mr. Kassberg's appointment, including:
- Cash compensation in accordance with the current non-executive director policy.
- Grant of non-incentive stock options effective September 30, 2024, under the 2020 Equity Incentive Plan.
- Vesting schedule: Substantially equal monthly installments over three years, contingent on continued service.
- Execution of a standard director indemnification agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the new option grant on dilution.
- Review the Company's 2020 Equity Incentive Plan to confirm remaining share availability.
- Confirm the specific cash compensation amount for non-executive directors as referenced in the filing.
- Assess Mr. Kassberg's prior roles at Ultragenyx and Corium International for potential strategic alignment.